The Bixdoo Standard · What’s Bixdoo?

Adocia

 Diabetes treatments using chaperon proteins

 Lyon, France

BINDEX

A

What's this?

Disruption

Region

B Basics

BASICS 

01Adocia is specialized in Diabetes treatment, working with therapeutic proteins using a patented BioChaperone® technology to achieve personalized therapies

HQ 

02Production in Lyon, France

Runway

2005

Founding year

People 

Gérard Soula
Founder & CEO

People 

Olivier Soula
R&D
Director

Employees 

135

People

K Keys

03Market Research shows the need for better treatments in diabetic patients to reduce long-term consequences.

Chaperones 

Unique Tech

The BioChaperone® technology is at the center of product strategy: 300 molecules are used to protect the drugs from degradation

They also enhance the drug effect, are relatively inexpensive and tested in other treatments, improving the time and costs to market.

Asia presence 

A foot in China

Tonghua Dongbao (THDB) is their partner in China, working to get their BioChaperone® Lispro ultra-fast insuline into the market.

THDB also manufactures a Combo product of Glargine + Lispro using Adocia tech

Dual Approach 

Two hormones products

The bi-hormonal M1Pram product, a mix of insulin and pramlintide improves blood sugar levels after eating, but also physiological functions during digestion, helping reduce symptons and weight gain for type 1 diabetes patients.

M1Pram is in clinical trials and is seeing real interest from the scientific community and pharmaceutical companies, as can help with automatic artificial pancreas.

P Products

04A portfolio built on two axis: make known products better through chaperone proteins and innovate with two hormone combinations

Product 

Combo

Diabetes

Combo is premixed of a fast and slow insulin, reducing the daily injections to only two in more intense treatments — 65% of the chinese insulin market is this form of mixed products.

Product 

Lispro

Diabetes

Biochaperone Lispro is a rapid insulin to use after eating

Product 

Glucagon

Hypoglycaemia

Their Glucagon product, a hormone that increases blood sugar, is the only one available for intramuscular injection, the quickest administration method in life-threatening conditions.

Product 

Glargine GLP-1

Diabetes

A mixed of insulin and a substance that activates the GLP1 receptor, it improves blood sugar ranges on patients needing more strength to control it.

Product 

Glucagon GLP-1

Obesity

The Glucagon GLP-1 mixes two hormones, glucagon and a substance called exenatide, that increase satiety, energy expenditure and slows down gastric emptying. Almost 13% of the world’s population is obese and more approaches to treat obesity are needed.

Product 

M1PRAM

Diabetes

Is a multi-hormone treatment for type 1 diabetes,mixing insuline with Pramlintide that helps with weight loss and insuline levels controls. The mix make it easier for patients, reducing the number of daily injections, key to treatment effectiveness. The drug may also help diabetic patients with their cognitive decline.

B The Biz

05Adocia license their innovations to pharmaceutical companies which will finish development and commercialization. This approach focused on early development needs less capital and provides better ROI.

Partnerships 

Adocia is open to partner with expertise in medical science, Late-stage clinical development, regulatory affairs and marketing

Partners 

THDB

In 2018 Adocia and Chinese insulin leader Tonghua Dongbao Pharmaceuticals Co. Ltd entered into a strategic alliance to commercialize insulin products in mainland China.

Stocks 

ADOC

Market: EPA

Funding 

75.1 M

US DOLLARS

Investors 

Status: Series B

CDC Enterprises
Idinvest Partners
Bioam Gestion
ACG Management
Societe Generale Asset Management

CSR 

Knowledge passage

The company welcomes students and researchers each year and sponsors a class of the École Superieure de Physique et de Chimie Industrielles de la Ville de de Paris (ESPCI), supporting students professionalization.

C Customers

06The number of diabetic patients is set to increase in the next decades around the world, specially in emerging countries

The customers 

Large pharmaceutical companies looking for innovation

Increased development of biosimilars and generics is obliging pharmaceutical companies to quickly replace their flagship products that have fallen into the public domain.

Fully Engaged 

Improved second generation

Adocia’s model fits with this approach, with the added advantage of improving existing products: it helps manage the medicinal product lifecycle by generating more efficient, patent-protected “second generation” agents for the companies that sell them

M The Market

07A global pandemic

Diabetes is a global pandemic, affecting more than 463 million people worldwide. Despite significant progress made in the treatment of diabetes over the last 30 years, there is still a significant medical need, with it estimated that nearly 79% of people with diabetes experience severe complications

Emerging countries 

Rapid Growth

More than 116 million of the 463 million people worldwide with diabetes live in China. Faced with this exponential growth, particularly in mass indications, these countries must rationalize healthcare costs.

+51% increase in the number of diabetic patients predicted in 2025

For all people with type 1 diabetes and around 25% of people with type 2 diabetes, insulin is a necessary treatment.

Market data 

Billions

In 2017, Novo Nordisk estimated that medicine and devices global costs for the treatment of diabetes were above $80 billion

P The People

08Adocia was founded in December 2005 by Gérard Soula and his two sons, Olivier and Rémi

49% Women

GENDER EQUALITY

37 Yrs old

Average employee age

80% on R&D

Employees working on
research

Founder & CEO

Gérard Soula

CEO

Chairman of the Board of Directors and Chief Executive Officer of Adocia since 2005, PhD in organic chemistry, graduate of IAD in Aix-Marseille and then MBA of IAE in Marseille. Co-author of more than 120 patents.

Founder

Olivier Soula

Deputy CEO and R&D Director

holder of a PhD in polymer physico-chemistry, graduate of ENSIC Mulhouse and graduate of the MBA of IAE Lyon. Co-author of 40 patents.